Lipella Pharmaceuticals INC
Lipella Pharmaceuticals Inc. was a clinical-stage biotechnology company that developed novel therapies using proprietary liposomal drug delivery technology, advancing multiple drug candidates into FDA-authorized clinical trials for conditions including oral lichen planus and hemorrhagic cystitis. The company obtained multiple Investigational New Drug authorizations from the U.S. Food and Drug Administration. In June 2026, Lipella completed a sale of its pharmaceutical development programs and associated intellectual property and regulatory assets to XRAIY LLC and concluded its research and development activities.
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Lipella Pharmaceuticals INC | Pittsburgh | PA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.